United Therapeutics Corporation (UTHR)
| Market Cap | 10.04B |
| Revenue (ttm) | 1.79B |
| Net Income (ttm) | 630.80M |
| Shares Out | 45.52M |
| EPS (ttm) | 13.24 |
| PE Ratio | 16.67 |
| Forward PE | 13.02 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 115,746 |
| Open | 220.66 |
| Previous Close | 220.41 |
| Day's Range | 217.08 - 224.06 |
| 52-Week Range | 158.38 - 245.48 |
| Beta | 0.53 |
| Analysts | Buy |
| Price Target | 247.97 (+12.4%) |
| Earnings Date | Aug 3, 2022 |
About UTHR
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension asso... [Read more...]
Financial Performance
In 2021, UTHR's revenue was $1.69 billion, an increase of 13.63% compared to the previous year's $1.48 billion. Earnings were $475.80 million, a decrease of -7.58%.
Financial StatementsAnalyst Forecast
According to 17 analysts, the average rating for UTHR stock is "Buy." The 12-month stock price forecast is 247.97, which is an increase of 12.37% from the latest price.
News
United Therapeutics (UTHR) Q2 Earnings Miss Estimates, Revenues Up
United Therapeutics' (UTHR) second-quarter earnings missed estimates, while sales beat the same. Higher sales of Orenitram and Tyvaso drove the top line in the quarter.
United Therapeutics (UTHR) Q2 Earnings Lag Estimates
United Therapeutics (UTHR) delivered earnings and revenue surprises of -41.22% and 0.85%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
United Therapeutics Corporation Reports Second Quarter 2022 Financial Results
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter en...
United Therapeutics (UTHR) Earnings Expected to Grow: What to Know Ahead of Q2 Release
United Therapeutics (UTHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
United Therapeutics Corporation to Report Second Quarter 2022 Financial Results Before the Market Opens on Wednesday,...
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its second quarter 2022 financial results before th...
What's in Store for United Therapeutics' (UTHR) Q2 Earnings?
United Therapeutics' (UTHR) investor focus is likely to have been on sales figures of Tyvaso, Remodulin and Orenitram in the second quarter, as these constitute a vast majority of the total revenues.
Why United Therapeutics (UTHR) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
3 Roaring Stocks to Hold for the Next 20 Years
Their persistent bullishness -- especially in this rocky environment -- is a testament to their long-term potential.
Here's Why United Therapeutics (UTHR) is a Great Momentum Stock to Buy
Does United Therapeutics (UTHR) have what it takes to be a top stock pick for momentum investors? Let's find out.
Buy These 3 Low-Beta Stocks to Sail Through a Choppy Market
It is imperative to build a portfolio of low-beta stocks to sail through a choppy market. United Therapeutics (UTHR), Sanderson (SAFM) and AMN Healthcare (AMN) are well poised to gain.
Best Momentum Stocks to Buy for June 21st
IMO, PAG and UTHR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on June 21, 2022.
Stock Market Falls, Oil Prices, Bond Yields Rise; United Therapeutics, Eli Lilly, Vertex Hold Up
Higher volume resulted in a distribution day for the indexes. Investor's Business Daily has been helping people invest smarter results by providing exclusive stock lists, investing data, stock market re...
United Therapeutics Provides an Update on Its Organ Printing Programs
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. & ROCK HILL, S.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that in partnership wi...
United Therapeutics Corporation to Present at the Jefferies Healthcare Conference
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that James Edgemond, Chief Financial Officer and Treasurer, will provid...
Why Is United Therapeutics (UTHR) Up 22.1% Since Last Earnings Report?
United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock?
The Nasdaq's Soaring, and Investors Are Watching These 2 Winning Stocks
A couple of tickers have managed to overcome market-wide weakness for all the right reasons.
United Therapeutics (UTHR) Gains on Tyvaso DPI Approval
The FDA approves United Therapeutics' (UTHR) drug-device combination therapy, Tyvaso DPI, for PAH patients. It is a dry-powder inhalation formulation of Treprostinil.
United Therapeutics Announces FDA Approval of Tyvaso DPI™
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the U.S. Food and Drug Administrati...
United Therapeutics (UTHR) Q1 Earnings & Sales Beat, Stock Up
United Therapeutics' (UTHR) first-quarter earnings and sales beat estimates. Higher sales of Orenitram and Tyvaso mainly drive the top line in the quarter.
United Therapeutics (UTHR) Q1 Earnings and Revenues Surpass Estimates
United Therapeutics (UTHR) delivered earnings and revenue surprises of 69.93% and 12.46%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
United Therapeutics Corporation Reports First Quarter 2022 Financial Results
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter en...
United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the 2022 American Tho...
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that eight posters and three mini-sympos...
United Therapeutics (UTHR) to Report Q1 Results: Wall Street Expects Earnings Growth
United Therapeutics (UTHR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.